Nanomedicine in Combination with Artificial Intelligence (AI): Transforming Cancer Treatment

Year : 2025 | Volume : | : | Page : –
    By

    D.Jeslin,

  • G.Vijayamma,

  • K.Antony Ajitha,

  • S.Gowtham,

  • N.Deepa,

  • S.Nirmala,

  • V.Harini,

  1. Faculty of Pharmacy, Department of Pharmaceutics, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India
  2. Faculty of Pharmacy, Department of Pharmaceutical Analysis, Faculty of Pharmacy, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India
  3. Faculty of Pharmacy, Department of Pharmaceutics, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, ,
  4. Faculty of Pharmacy, Department of Pharmaceutics, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India
  5. Faculty of Pharmacy, Department of Pharmacognosy, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India
  6. Faculty of Pharmacy, Department of Pharmacognosy, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India
  7. Faculty of Pharmacy, Department of Pharmacognosy, Sree Balaji Medical College and Hospital Campus, Bharath Institute of Higher Education and Research, Chromepet, Chennai-44, Tamil Nadu, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_151152’);});Edit Abstract & Keyword

The convergence of nanomedicine and artificial intelligence (AI) holds transformative potential for advancing cancer treatment, particularly in liver cancer. Nanomedicine enables the development of targeted drug delivery systems, enhanced imaging modalities, and precise therapeutic interventions, while AI facilitates data-driven decision-making, personalized treatment plans, and predictive analytics. This synergistic approach can significantly improve the diagnosis, treatment, and monitoring of liver cancer by optimizing the use of nanoparticle-based therapies. AI-powered algorithms can analyze complex patient data, including genetic profiles, imaging results, and tumor characteristics, to tailor nanoparticle formulations for targeted therapy and enhance the efficacy of immunotherapies. Additionally, AI can optimize drug combinations, overcome resistance mechanisms, and monitor real-time treatment responses, ensuring that therapies are both effective and adaptive. Despite the promise of this integration, challenges such as data privacy, regulatory hurdles, and the ethical implications of AI-driven decision-making must be addressed. The combined capabilities of nanomedicine and AI represent a paradigm shift in the treatment of liver cancer, offering more personalized, efficient, and precise approaches to cancer care.

Keywords: Nanomedicine, Drug Resistance, Clinical decision support systems, Personalized Drug Delivery, AI in Immunotherapy.

How to cite this article:
D.Jeslin, G.Vijayamma, K.Antony Ajitha, S.Gowtham, N.Deepa, S.Nirmala, V.Harini. Nanomedicine in Combination with Artificial Intelligence (AI): Transforming Cancer Treatment. Trends in Drug Delivery. 2025; ():-.
How to cite this URL:
D.Jeslin, G.Vijayamma, K.Antony Ajitha, S.Gowtham, N.Deepa, S.Nirmala, V.Harini. Nanomedicine in Combination with Artificial Intelligence (AI): Transforming Cancer Treatment. Trends in Drug Delivery. 2025; ():-. Available from: https://journals.stmjournals.com/tdd/article=2025/view=0

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_151152’);});Edit

References

1. Sarhadi, V. K., & Armengol, G. (2022). Molecular Biomarkers in Cancer. Biomolecules, 12(8), 1021. https://doi.org/10.3390/biom12081021 .
2. Stachowicz-Stencel, T., & Synakiewicz, A. (2020). Biomarkers for Pediatric Cancer Detection: Latest Advances and Future Perspectives. Biomarkers in Medicine, 14(5), 391–400. https://doi.org/10.2217/bmm-2019-0613 .
3. Poondla N, Chandrasekaran AP, Kim KS, Ramakrishna S. Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? BMB Rep. 2019 Mar;52(3):181-189. doi: 10.5483/BMBRep.2019.52.3.048.
4. Yazdani M, Beiki Z, Jahanian A. RNA secondary structured logic gates for profiling the microRNA cancer biomarkers. IET Nanobiotechnol. 2020 May;14(3):181-190.
5. Lamlertthon W, Hayward MC, Hayes DN. Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools. Cancer J. 2011 Nov-Dec;17(6):451-64
6. Armakolas, A., Kotsari, M., & Koskinas, J. (2023). Liquid Biopsies, Novel Approaches and Future Directions. Cancers, 15(5), 1579. https://doi.org/10.3390/cancers15051579
7. Marrugo-Ramírez, J., Mir, M., & Samitier, J. (2018). Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. International Journal of Molecular Sciences, 19(10), 2877. https://doi.org/10.3390/ijms19102877
8. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol. 2007 Jun;18(6):1043-50 https://doi.org/10.1093/annonc/mdm072 .
9. Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Inform. 2022 Feb 7;21:
10. Eslami-S Z, Cortés-Hernández LE, Cayrefourcq L, Alix-Panabières C. The Different Facets of Liquid Biopsy: A Kaleidoscopic View. Cold Spring Harb Perspect Med. 2020 Jun 1;10(6):a037333.
11. Arechederra M, Ávila MA, Berasain C. Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Adv Lab Med. 2020 Apr 27;1(3):20200009.

12. Brock, G., Castellanos-Rizaldos, E., Hu, L., Coticchia, C. and Skog, J., 2015. Liquid biopsy for cancer screening, patient stratification and monitoring. Translational Cancer Research, 4(3).
13. Scarlotta M, Simsek C, Kim AK. Liquid Biopsy in Solid Malignancy. Genet Test Mol Biomarkers. 2019 Apr;23(4):284-296.
14. Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book. 2016;35:e493-503.
15. Duffy MJ, Crown J. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Clin Chem. 2019 Oct;65(10):1228- 1238.
16. Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel). 2019 Jul 3;11(7):935.
17. Demir Karaman E, Işık Z. Multi-Omics Data Analysis Identifies Prognostic Biomarkers across Cancers. Med Sci (Basel). 2023 Jun 27;11(3):44.
18. Heo YJ, Hwa C, Lee GH, Park JM, An JY. Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes. Mol Cells. 2021 Jul 31;44(7):433-443.
19. Raufaste-Cazavieille V, Santiago R, Droit A. Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology. Front Mol Biosci. 2022 Oct 11;9:962743
20. Vlachavas EI, Bohn J, Ückert F, Nürnberg S. A Detailed Catalogue of Multi-Omics Methodologies for Identification of Putative Biomarkers and Causal Molecular Networks in Translational Cancer Research. Int J Mol Sci. 2021 Mar 10;22(6):2822.

21. Verma M. Epigenetic biomarkers in cancer epidemiology. Methods Mol Biol.
2012;863:467-80.

22. García-Giménez JL, Mena-Mollá S, Beltrán-García J, Sanchis-Gomar F. Challenges in the analysis of epigenetic biomarkers in clinical samples. Clin Chem Lab Med. 2017 Aug 28;55(10):1474-1477.
23. Li CC, Wang ZY, Wang LJ, Zhang CY. Biosensors for epigenetic biomarkers detection: A review. Biosens Bioelectron. 2019 Nov 1;144:111695.
24. Taj, A., Rehman, A. and Bajwa, S.Z., 2020. Biomarkers and their role in detection of biomolecules. Nanobiosensors: From design to applications, pp.73-94.
25. Park H, Hwang MP, Lee KH. Immunomagnetic nanoparticle-based assays for detection of biomarkers. Int J Nanomedicine. 2013;8:4543-52.
26. Viswambari Devi R, Doble M, Verma RS. Nanomaterials for early detection of cancer biomarker with special emphasis on gold nanoparticles in immunoassays/sensors. Biosens Bioelectron. 2015 Jun 15;68:688-698.
27. Sharifianjazi F, Jafari Rad A, Bakhtiari A, Niazvand F, Esmaeilkhanian A, Bazli L, Abniki M, Irani M, Moghanian A. Biosensors and nanotechnology for cancer diagnosis (lung and bronchus, breast, prostate, and colon): a systematic review. Biomed Mater. 2021 Dec 24;17(1).
28. Masi, A., Antonacci, A., Moccia, M., Frisulli, V., De Felice, M., De Falco, M. and Scognamiglio, V., 2023. CRISPR-Cas assisted diagnostics: A broad application biosensing approach. TrAC Trends in Analytical Chemistry, 162, p.117028.
29. Gong S, Zhang S, Lu F, Pan W, Li N, Tang B. CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection. Anal Chem. 2021 Sep 7;93(35):11899-11909.
30. Singh, S., Thakran, R., Kaushal, A., Saini, R.V., Saini, A. and Datta, S., 2024. Crispr-cas based biosensing: A fast-expanding molecular diagnostic tool. Microchemical Journal, p.110421
31. Bao M, Chen Q, Xu Z, Jensen EC, Liu C, Waitkus JT, Yuan X, He Q, Qin P, Du K. Challenges and Opportunities for Clustered Regularly Interspaced Short Palindromic Repeats Based Molecular Biosensing. ACS Sens. 2021 Jul 23;6(7):2497-2522.
32. Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. Biomolecules. 2022 Jul 23;12(8):1021
33. Stachowicz-Stencel T, Synakiewicz A. Biomarkers for pediatric cancer detection: latest advances and future perspectives. Biomark Med. 2020 Apr;14(5):391-400.
34. Poondla N, Chandrasekaran AP, Kim KS, Ramakrishna S. Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? BMB Rep. 2019 Mar;52(3):181-189.
35. Yazdani M, Beiki Z, Jahanian A. RNA secondary structured logic gates for profiling the microRNA cancer biomarkers. IET Nanobiotechnol. 2020 May;14(3):181-190.
36. Lamlertthon W, Hayward MC, Hayes DN. Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools. Cancer J.2011 Nov-Dec;17(6):451-64.
37. Rade J, Zhang J, Sarkar S, Krishnamurthy A, Ren J, Sarkar A. Deep Learning for Live Cell Shape Detection and Automated AFM Navigation. Bioengineering (Basel). 2022 Oct 5;9(10):522.
38. Sanchez-Morillo D, León-Jiménez A, Guerrero-Chanivet M, Jiménez-Gómez G, Hidalgo-Molina A, Campos-Caro A. Integrating routine blood biomarkers and artificial intelligence for supporting diagnosis of silicosis in engineered stone workers. Bioeng Transl Med. 2024; 9(6):e10694.
39. Cai, Guangyao et al. Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in China: a multicentre, retrospective cohort study.march 2024.The Lancet Digital Health, Volume 6, Issue 3, e176 – e186.
40. Soerensen, Patricia Diana, Christensen, Henry, Gray Worsoe Laursen, Soeren, Hardahl, Christian, Brandslund, Ivan and Madsen, Jonna Skov. “Using artificial intelligence in a primary care setting to identify patients at risk for cancer: a risk prediction model based on routine laboratory tests” Clinical Chemistry and Laboratory Medicine (CCLM), vol. 60, no. 12, 2022, pp. 2005-2016 https://doi.org/10.1515/cclm-2021-1015 .

Ahead of Print Subscription Review Article
Volume
Received 22/01/2025
Accepted 27/01/2025
Published 30/01/2025
157